Optomed Oyj

Board/Management Information • Sep 11, 2020

Disclosure 387046

Optomed Oyj - Other information disclosed according to the rules of the Exchange

Composition of Optomed’s Nomination Board

Optomed Plc Stock Exchange Release 11 September 2020 at 12.00, Helsinki Composition of Optomed’s Nomination Board According to Optomed’s shareholder register of 1 September 2020, the shareholders represented in the shareholders’ Nomination Board are Cenova Capital’s controlled entities (Alnair Investments, Cenova China Healthcare Fund IV and Shanghai Cenova Innovation Venture Fund (Limited Partnership)), Robert Bosch Venture Capital GmbH and Aura Capital Oy. These shareholders have appointed the following persons to the Nomination Board: · Hai Wu, Cenova Capital · Ingo Ramesohl, Robert Bosch Venture Capital GmbH · Jarmo Malin, Aura Capital Oy Petri Salonen, Chairman of Optomed’s Board of Directors, will serve as the Nomination Board's expert member. According to the resolution of Optomed General Meeting, the Optomed Nomination Board consists of the representatives of Optomed three largest shareholders as of the first trading day September, and the Chairman of the Board of Directors as an expert member. Should a shareholder not wish to exercise the nomination right, the right shall be transferred to the next largest shareholder who otherwise would not be entitled to nominate a member. The Nomination Board is to prepare proposals on the composition and members of the Board of Directors and their remuneration for the next Annual General Meeting and it will submit its proposal to the Board of Directors 31 January 2021 at the latest. Optomed Plc Further enquiries Petri Salonen, Chairman of the Board, Optomed Plc, petri.salonen@optomed.com Sakari Knuutti, CLO, Optomed Plc, sakari.knuutti@optomed.com Optomed in Brief Optomed is a Finnish medical technology company and one of the leading providers of handheld fundus cameras. Optomed combines handheld cameras with software and artificial intelligence with the aim to transform the diagnostic process of blinding eye-diseases such as rapidly increasing diabetic retinopathy. In its business Optomed focuses on eye-screening devices and software solutions related R&D in Finland and sales through different channels in over 60 countries. The company has an extensive portfolio of 55 international patents protecting the technology. In 2019, Optomed’s revenue reached EUR 15 million and 2018 pro forma revenue amounted to EUR 14.5 million. At the end of 2019, Optomed employed 108 professionals.